FMP
SeaStar Medical Holding Corporation
ICU
NASDAQ
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
1.27 USD
0.02 (1.57%)
ICU Financial Statements
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Total Revenue
67k
68k
0
0
Cost of Revenue
0
0
0
0
Gross Profit
67k
68k
0
0
Operating Expenses
4.83M
4.52M
4.67M
3.95M
Research and Development
2.74M
2.34M
2.33M
1.7M
Selling, General & Administrative Expenses
2.1M
2.19M
2.33M
2.25M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
2.1M
2.19M
2.33M
2.25M
Other Expenses
0
0
0
0
Operating Income
-4.77M
-4.46M
-4.67M
-3.95M
Total Other Income/Expenses Net
348k
-22k
1.44M
-8.75M
Income Before Tax
-4.42M
-4.48M
-3.23M
-12.7M
Income Tax
0
0
3k
-3.95M
Net Income
-4.42M
-4.48M
-3.24M
-12.7M
Basic EPS
-0.9
-1.1
-1.03
-4.73
EPS Diluted
-0.9
-1.1
-1.03
-4.73
Basic Average Shares
4.92M
4.09M
3.15M
2.68M
Diluted Average Shares
4.92M
4.09M
3.15M
2.68M
EBITDA
-4.67M
-4.21M
-3.15M
-12.55M
Retained Earning Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Retained Earnings (Previous Year)
-135.15M
-130.67M
-127.43M
-114.73M
Net Income
-4.42M
-4.48M
-3.24M
-12.7M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-139.56M
-135.15M
-130.67M
-127.43M
Other Distributions
-4.42M
-4.48M
-3.24M
-12.7M
PPE Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Gross PPE
0
0
0
0
Annual Depreciation
0
250k
1.52M
3.95M
Capital Expenditure
0
0
0
0
Net PPE
0
-250k
-1.52M
-3.95M
Intangible and Goodwill Schedule
Quarter
2024 Q4
2024 Q3
2024 Q2
2024 Q1
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
